Audrey Sarry

1.8k total citations
27 papers, 514 citations indexed

About

Audrey Sarry is a scholar working on Hematology, Genetics and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Audrey Sarry has authored 27 papers receiving a total of 514 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Hematology, 10 papers in Genetics and 7 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Audrey Sarry's work include Acute Myeloid Leukemia Research (25 papers), Acute Lymphoblastic Leukemia research (7 papers) and Hematopoietic Stem Cell Transplantation (6 papers). Audrey Sarry is often cited by papers focused on Acute Myeloid Leukemia Research (25 papers), Acute Lymphoblastic Leukemia research (7 papers) and Hematopoietic Stem Cell Transplantation (6 papers). Audrey Sarry collaborates with scholars based in France and United States. Audrey Sarry's co-authors include Sarah Bertoli, Christian Récher, Françoise Huguet, Emilie Bérard, Éric Delabesse, Suzanne Tavitian, François Vergez, Isabelle Luquet, Éliane Duchayne and Anne Huynh and has published in prestigious journals such as Blood, PLoS ONE and Medicine.

In The Last Decade

Audrey Sarry

27 papers receiving 509 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Audrey Sarry France 12 410 152 118 103 103 27 514
Jassada Buaboonnam Thailand 11 273 0.7× 167 1.1× 111 0.9× 146 1.4× 166 1.6× 28 571
Mohamed Elhamri France 14 323 0.8× 181 1.2× 91 0.8× 159 1.5× 114 1.1× 44 507
Maria Aparecida Zanichelli Brazil 12 226 0.6× 105 0.7× 179 1.5× 194 1.9× 63 0.6× 28 469
C. L. Beach United States 10 783 1.9× 428 2.8× 241 2.0× 78 0.8× 125 1.2× 36 989
Maxim Norkin United States 12 231 0.6× 86 0.6× 52 0.4× 148 1.4× 41 0.4× 35 396
Yoo Jin Lee South Korea 10 185 0.5× 83 0.5× 59 0.5× 77 0.7× 69 0.7× 50 334
Luciana Correa Oliveira de Oliveira Brazil 10 181 0.4× 138 0.9× 60 0.5× 88 0.9× 38 0.4× 31 330
J. Timothy Caldwell United States 13 251 0.6× 376 2.5× 43 0.4× 114 1.1× 83 0.8× 18 578
Luís Villela Mexico 12 152 0.4× 94 0.6× 73 0.6× 139 1.3× 55 0.5× 33 384
Wilson Grandin United States 4 456 1.1× 235 1.5× 187 1.6× 61 0.6× 84 0.8× 5 551

Countries citing papers authored by Audrey Sarry

Since Specialization
Citations

This map shows the geographic impact of Audrey Sarry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Audrey Sarry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Audrey Sarry more than expected).

Fields of papers citing papers by Audrey Sarry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Audrey Sarry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Audrey Sarry. The network helps show where Audrey Sarry may publish in the future.

Co-authorship network of co-authors of Audrey Sarry

This figure shows the co-authorship network connecting the top 25 collaborators of Audrey Sarry. A scholar is included among the top collaborators of Audrey Sarry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Audrey Sarry. Audrey Sarry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leroy, Harmony, Emilie Bérard, Isabelle Luquet, et al.. (2024). Dismal outcome of refractory or relapsing patients with myelodysplasia‐related acute myeloid leukemia partially alleviated by intensive chemotherapy. Cancer Medicine. 13(3). e7003–e7003. 1 indexed citations
2.
Alliot, Jean‐Marc, Pierre‐Yves Dumas, François Vergez, et al.. (2024). Artificial intelligence-based prediction models for acute myeloid leukemia using real-life data: A DATAML registry study. Leukemia Research. 136. 107437–107437. 10 indexed citations
3.
Mouchel, Pierre‐Luc, Emilie Bérard, Suzanne Tavitian, et al.. (2023). Vitamin C and D supplementation in acute myeloid leukemia. Blood Advances. 7(22). 6886–6897. 10 indexed citations
4.
Simoncini, David, François Vergez, Pierre‐Yves Dumas, et al.. (2021). Artificial Intelligence-Based Predictive Models for Acute Myeloid Leukemia. Blood. 138(Supplement 1). 3389–3389. 2 indexed citations
5.
Vergez, François, Marie-Laure Nicolau-Travers, Sarah Bertoli, et al.. (2020). CD34+CD38−CD123+ Leukemic Stem Cell Frequency Predicts Outcome in Older Acute Myeloid Leukemia Patients Treated by Intensive Chemotherapy but Not Hypomethylating Agents. Cancers. 12(5). 1174–1174. 11 indexed citations
6.
Dumas, Pierre‐Yves, Sarah Bertoli, Emilie Bérard, et al.. (2020). Real-World Outcomes of Patients with Refractory or Relapsed FLT3-ITD Acute Myeloid Leukemia: A Toulouse-Bordeaux DATAML Registry Study. Cancers. 12(8). 2044–2044. 5 indexed citations
7.
Bertoli, Sarah, Pierre‐Yves Dumas, Emilie Bérard, et al.. (2020). Outcome of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia before Second-Generation FLT3 Tyrosine Kinase Inhibitors: A Toulouse–Bordeaux DATAML Registry Study. Cancers. 12(4). 773–773. 7 indexed citations
8.
Bories, Pierre, Naïs Prade, Bastien Cabarrou, et al.. (2020). Impact of TP53 mutations in acute myeloid leukemia patients treated with azacitidine. PLoS ONE. 15(10). e0238795–e0238795. 13 indexed citations
9.
Largeaud, Laëtitia, Emilie Bérard, Sarah Bertoli, et al.. (2019). Outcome of AML patients with IDH2 mutations in real world before the era of IDH2 inhibitors. Leukemia Research. 81. 82–87. 6 indexed citations
10.
11.
Bertoli, Sarah, Étienne Paubelle, Emilie Bérard, et al.. (2018). Ferritin heavy/light chain (FTH1/FTL) expression, serum ferritin levels, and their functional as well as prognostic roles in acute myeloid leukemia. European Journal Of Haematology. 102(2). 131–142. 69 indexed citations
12.
Bertoli, Sarah, Muriel Picard, Emilie Bérard, et al.. (2018). Dexamethasone in hyperleukocytic acute myeloid leukemia. Haematologica. 103(6). 988–998. 42 indexed citations
13.
Bertoli, Sarah, Suzanne Tavitian, Anne Huynh, et al.. (2017). Improved outcome for AML patients over the years 2000–2014. Blood Cancer Journal. 7(12). 635–635. 50 indexed citations
14.
Bertoli, Sarah, Suzanne Tavitian, Lucie Obéric, et al.. (2016). Therapy-related acute myeloid leukemia following treatment of lymphoid malignancies. Oncotarget. 7(52). 85937–85947. 10 indexed citations
15.
Borel, Cécile, Emilie Bérard, Marylise Fort, et al.. (2016). Prognostic impact of viral reactivations in acute myeloid leukemia patients undergoing allogeneic stem cell transplantation in first complete response. Medicine. 95(48). e5356–e5356. 5 indexed citations
16.
Bertoli, Sarah, Suzanne Tavitian, Audrey Sarry, et al.. (2016). Is Intermediate-Dose Cytarabine a Good Control for Patients with Relapsed or Refractory Acute Myeloid Leukemia?. Blood. 128(22). 3991–3991. 2 indexed citations
17.
Récher, Christian, Sarah Bertoli, Muriel Picard, et al.. (2016). Dexamethasone Reduces Incidence of Relapse and Improves Overall Survival in Hyperleucocytic Acute Myeloid Leukemia. Blood. 128(22). 1636–1636. 2 indexed citations
18.
Bories, Pierre, Sarah Bertoli, Emilie Bérard, et al.. (2014). Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. American Journal of Hematology. 89(12). E244–52. 37 indexed citations
19.
Bertoli, Sarah, Emilie Bérard, Françoise Huguet, et al.. (2013). Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 121(14). 2618–2626. 76 indexed citations
20.
LaRochelle, Olivier, Sarah Bertoli, François Vergez, et al.. (2011). Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget. 2(11). 850–861. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jassada Buaboonnam Breakdown of academic impact, for papers by Mohamed Elhamri Breakdown of academic impact, for papers by Maria Aparecida Zanichelli Breakdown of academic impact, for papers by C. L. Beach Breakdown of academic impact, for papers by Maxim Norkin Breakdown of academic impact, for papers by Yoo Jin Lee Breakdown of academic impact, for papers by Luciana Correa Oliveira de Oliveira Breakdown of academic impact, for papers by J. Timothy Caldwell Breakdown of academic impact, for papers by Luís Villela Breakdown of academic impact, for papers by Wilson Grandin
Rankless by CCL
2026